CAR T
Published on August 15, 2024
Anti-CD3 mAb for immune modulation in late-gestation transplantation
by Blood Advances
Riley JS, Berkowitz CL, Luks VL, et al. Immune Modulation Permits Tolerance and Engraftment in a Murine Model of Late-Gestation Transplantation. Blood Advances. 2024; (doi: 10.1182/bloodadvances.2023012247).
Scientists suspect immune modulation with anti-CD3 monoclonal antibody (mAb) can unlock the potential of in utero hematopoietic cell transplantation, an experimental intervention that aims to treat sickle cell and other disorders before a child is even born. The non-myeloablative procedure is complex even in the earliest weeks of pregnancy and excluded fetuses evaluated after the first trimester, when T-cell immunity begins to develop. However, tests in mice undergoing neonatal transplantation at 20 days post-coitum offer hope for late-gestation transplantation. Administering anti-CD3 mAb with transplantation safely and effectively mediates transient T cell depletion — which, in turn, provides more time for donor-specific central tolerance induction to occur. With this strategy, researchers believe sustained allogeneic engraftment is possible even in the context of late-gestation transplantation.
Read More
![]()